Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 4NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 38Neoplasms 19Breast Neoplasms 9Head and Neck Neoplasms 5Colorectal Neoplasms 3Neoplasm Metastasis 2Carcinoma, Squamous Cell 2Adenocarcinoma 2Urologic Neoplasms 1Stomach Neoplasms 1Squamous Non-small Cell Lung Cancer 1Solid Tumors 1Rhabdomyosarcoma 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neuroectodermal Tumors 1NSCLC Harboring NRG1 Fusion 1Lung Neoplasms 1Glioma 1Glioblastoma 1Colonic Neoplasms 1Advanced Solid Tumors 1

Interventions

Gemcitabine 205130-nm albumin-bound paclitaxel 84Albumin-Bound Paclitaxel 57pembrolizumab 43Fluorouracil 41Leucovorin 34Oxaliplatin 33Capecitabine 25Nivolumab 22Irinotecan 19Bevacizumab 17Paclitaxel 16Cyclophosphamide 15Cetuximab 15Taxes 13Erlotinib Hydrochloride 13Drug Therapy 13Carboplatin 12irinotecan sucrosofate 11Injections 10Cisplatin 9fludarabine 8ALT-803 8spartalizumab 7olaparib 7avelumab 7Pemetrexed 7Docetaxel 7ruxolitinib 6TH 302 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Pancreatic Neoplasms × Afatinib × Clear all
NCT03785249 2025-09-30

Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1

Mirati Therapeutics Inc.

Phase 1/2 Active not recruiting
731 enrolled 1 FDA
Gastrointestinal

Colonic Neoplasms, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡